欧洲随机对照试验:呼吁保护国家医疗系统免受肾衰竭浪潮冲击
文章指出慢性肾脏病预计到2050年成为全球第三大死因,但急性肾损伤无欧洲药品管理局批准的治疗,透析患者无药物显示生存获益。随机对照试验在肾内科面临患者异质性、多病共存、高脱落率等挑战,欧洲还受临床试验法规实施碎片化、安全报告要求过重和缺乏肾脏病特异性指南的额外障碍。减少临床试验官僚主义联盟发布建议,欧洲肾脏协会支持这些建议,呼吁监管协调、简化安全报告和以患者为中心的知情同意。
要点
- 慢性肾脏病预计2050年成为全球第三大死因,但治疗创新有限。
- 急性肾损伤无欧洲药品管理局批准的治疗,透析患者无药物显示生存获益。
- 欧洲肾脏病随机对照试验受法规碎片化、安全报告过重和缺乏特异性指南阻碍。
核心结论
- 实施监管协调、简化安全报告和以患者为中心的知情同意等措施,对在欧洲开展高效高质量的肾脏病试验至关重要。
主要发现
- 慢性肾脏病预计到2050年成为全球第三大死因。
- 无欧洲药品管理局批准的急性肾损伤治疗,无药物在透析患者中显示生存获益。
- 肾内科随机对照试验面临患者异质性、多病共存、高脱落率和罕见病小人群等挑战。
- 欧洲临床试验法规实施碎片化、安全报告要求过重和缺乏肾脏病特异性指南阻碍学术主导研究。
临床怎么用
- 欧洲肾脏协会支持减少临床试验官僚主义联盟的建议,呼吁监管协调、简化安全报告和以患者为中心的知情同意。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Kidney diseases are among the fastest-growing global health burdens, with chronic kidney disease projected to become the third leading cause of death by 2050. Despite this, therapeutic innovation remains limited: no European Medicines Agency-approved treatment exists for acute kidney injury, and no drugs have demonstrated survival benefits in patients on dialysis. Randomized controlled clinical trials, although pivotal for advancing care, face persistent challenges in nephrology, including patient heterogeneity, multimorbidity, high dropout rates and small populations in rare diseases. In Europe, these intrinsic obstacles are compounded by fragmented implementation of the Clinical Trials Regulation (536/2014), excessive safety reporting demands and lack of nephrology-specific guidance, discouraging academic-led initiatives and limiting pragmatic research. The Coalition for Reducing Bureaucracy in Clinical Trials, a broad alliance of medical societies and patient advocates, has recently published the 'Clinical research in Europe: putting quality and patient safety first' recommendations calling for regulatory harmonization, simplified safety reporting and patient-centred consent. The European Renal Association, a member of the Coalition and contributor to the report, fully supports these recommendations. Implementing such measures is critical to fostering efficient, high-quality nephrology trials in Europe and delivering urgently needed, evidence-based, life-saving and safe therapies for patients with kidney disease.
引用
- Ortiz A, Arici M, Goumenos DS, et al. Randomized controlled trials in Europe: a call to action to protect national healthcare systems from the upcoming tsunami of kidney failure. Nephrol Dial Transplant. 2026. PMID: 41578941. doi:10.1093/ndt/gfag007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。